{"id":"peginterferon-alfa-2a-and-tenofovir","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Headache"},{"rate":"10-30%","effect":"Nausea"},{"rate":"5-20%","effect":"Diarrhea"},{"rate":"5-20%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL1201560","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Peginterferon-alfa 2a works by stimulating the body's immune response to fight viral infections, while tenofovir inhibits the replication of viral DNA by blocking the action of reverse transcriptase. This combination of mechanisms makes peginterferon-alfa 2a and tenofovir effective against a range of viral infections.","oneSentence":"Peginterferon-alfa 2a is an interferon that modulates the immune system to treat viral infections, while tenofovir is a nucleotide reverse transcriptase inhibitor that blocks viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:43.425Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B"},{"name":"Chronic hepatitis C"}]},"trialDetails":[{"nctId":"NCT02577029","phase":"PHASE2","title":"Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-12","conditions":"Hepatitis B, Hepatitis D","enrollment":79},{"nctId":"NCT04439539","phase":"PHASE2","title":"A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-14","conditions":"Hepatitis B, Chronic","enrollment":54},{"nctId":"NCT04585789","phase":"PHASE2","title":"A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-03-11","conditions":"Hepatitis B","enrollment":24},{"nctId":"NCT05244057","phase":"PHASE2","title":"A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients","status":"COMPLETED","sponsor":"Shanghai HEP Pharmaceutical Co., Ltd.","startDate":"2022-08-23","conditions":"Chronic Hepatitis B","enrollment":8},{"nctId":"NCT04667104","phase":"PHASE2","title":"A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-02-01","conditions":"Hepatitis B, Chronic","enrollment":48},{"nctId":"NCT05005507","phase":"PHASE2","title":"A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-11-03","conditions":"Hepatitis B, Chronic","enrollment":1},{"nctId":"NCT01369212","phase":"PHASE3","title":"Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2012-11","conditions":"Hepatitis B","enrollment":201},{"nctId":"NCT00100581","phase":"NA","title":"Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis C","enrollment":2},{"nctId":"NCT03013556","phase":"PHASE4","title":"Study on an Optimal Antiviral Treatment in HBeAg Positive Chronic Hepatitis B Patients","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2016-11","conditions":"Chronic Hepatitis","enrollment":180},{"nctId":"NCT02888106","phase":"PHASE2","title":"Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent","status":"COMPLETED","sponsor":"Hepatera Ltd.","startDate":"2016-04","conditions":"Chronic Viral Hepatitis B With Delta-agent","enrollment":90},{"nctId":"NCT00973219","phase":"NA","title":"Hepatitis B Surface Antigen(HBsAg) Loss in Chronic Hepatitis B Patients With Low Viral Load","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2009-09","conditions":"Chronic Hepatitis B","enrollment":151},{"nctId":"NCT03957629","phase":"NA","title":"Optimized Treatment of Peginterferon Alfa 2a in Treatment Experienced Patients With HBV Related Liver Fibrosis","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2019-11-06","conditions":"Hepatitis B, Liver Fibrosis","enrollment":186},{"nctId":"NCT01373684","phase":"PHASE4","title":"PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B Patients","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2012-05-25","conditions":"Chronic Hepatitis B","enrollment":90},{"nctId":"NCT02565719","phase":"PHASE2","title":"REP 2139-Mg and REP 2165-Mg Combination Therapy in Chronic Hepatitis B Infection","status":"COMPLETED","sponsor":"Replicor Inc.","startDate":"2016-03","conditions":"Chronic Hepatitis B","enrollment":40},{"nctId":"NCT03920605","phase":"NA","title":"Optimized Treatment of Peginterferon Alfa 2a/2b in Treatment Experienced Patients With HBV Related Liver Fibrosis","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2019-02-01","conditions":"Hepatitis B, Liver Fibrosis","enrollment":100},{"nctId":"NCT02908191","phase":"PHASE1","title":"A Study in Healthy Volunteers and Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2016-11","conditions":"Chronic Hepatitis B","enrollment":86},{"nctId":"NCT03733652","phase":"NA","title":"Optimal Treatment for Poor Efficacy of Entecavir in Chronic Hepatitis B Patients","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2018-11-15","conditions":"Chronic Hepatitis b, Efficacy, Self","enrollment":100},{"nctId":"NCT03109730","phase":"PHASE1, PHASE2","title":"Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2017-06-15","conditions":"Chronic Hepatitis B","enrollment":38},{"nctId":"NCT01277601","phase":"PHASE4","title":"Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-04","conditions":"Chronic Hepatitis B","enrollment":751},{"nctId":"NCT02644538","phase":"PHASE4","title":"Addition of PegIFN Alfa-2a to CHB Patients Treated With Nucleot(s)Ides","status":"UNKNOWN","sponsor":"The Second Affiliated Hospital of Chongqing Medical University","startDate":"2015-12","conditions":"Hepatitis B","enrollment":196},{"nctId":"NCT02560649","phase":"PHASE4","title":"An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2015-05","conditions":"Chronic Hepatitis B","enrollment":324},{"nctId":"NCT00391638","phase":"PHASE2, PHASE3","title":"Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2007-01","conditions":"Hepatitis B, HIV Infections","enrollment":56},{"nctId":"NCT01565889","phase":"PHASE1, PHASE2","title":"Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-03","conditions":"Hepatitis C, HIV","enrollment":52},{"nctId":"NCT00221286","phase":"PHASE3","title":"Efficacy and Safety of PegIFN +/- FTC / TDF to Treat Chronic Hepatitis B in HIV-Coinfected Patients","status":"TERMINATED","sponsor":"University Hospital, Bonn","startDate":"2004-09","conditions":"Chronic Hepatitis B, HIV Infections","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Hepatitis B","PEGASYS","Viread","tenofovir"],"phase":"phase_3","status":"active","brandName":"Peginterferon-alfa 2a and tenofovir","genericName":"Peginterferon-alfa 2a and tenofovir","companyName":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","companyId":"national-institute-of-diabetes-and-digestive-and-kidney-diseases-niddk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Peginterferon-alfa 2a is an interferon that modulates the immune system to treat viral infections, while tenofovir is a nucleotide reverse transcriptase inhibitor that blocks viral replication. Used for Chronic hepatitis B, Chronic hepatitis C.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}